Health
Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
Johnson & Johnson (NYSE: JNJ) announced today that 11 abstracts featuring new data on its robust portfolio and pipeline in neuropsychiatry will be presented at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held from January 12-15, in Nassau, Bahamas. Presentations include the latest research from across the Company's neuropsychiatry portfolio, including major depressive disorder (MDD) and treatment-resistant depression (TRD), as well as preclinical and transl
About this update from Johnson & Johnson
[{"type":"text","content":"New CAPLYTA® (lumateperone) Phase 3 analyses evaluating efficacy in achieving remission in adjunctive major depressive disorder (aMDD) to be presented ","length":150,"tagName":"p"},{"type":"text","content":"SPRAVATO® (esketamine) effects on anhedonia in treatment-resistant depression (TRD) – Phase 3 data post-hoc analyses to be presented","length":132,"tagName":"p"},{"type":"text","content":"Comparative tolerability of adjunctive seltorexant vs. adjunctive quetiapine XR in major depressive disorder (MDD) with insomnia symptoms – new Phase 3 metabolic analyses will also be presented","length":193,"tagName":"p","attribs":{}},{"type":"text","content":"TITUSVILLE, N.J., Jan. 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 11 abstracts featuring new data on its robust portfolio and pipeline in neuropsychiatry will be presented at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held from January 12-15, in Nassau, Bahamas. Presentations include the latest research from across the Company's neuropsychiatry portfolio, including major depressive disorder (MDD) and treatment-resistant depression (TRD), as well as preclinical and translational neuropsychiatric research.","length":595,"tagName":"p"},{"type":"image","alt":"Johnson & Johnson (PRNewsfoto/Johnson & Johnson)","displaySize":"","headline":null,"caption":"Johnson & Johnson (PRNewsfoto/Johnson & Johnson)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":38,"url":"https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/l1P3ZFYFL52xeQr0zq6rKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY3O2NmPXdlYnA-/https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721","width":400,"height":38}},"href":"https://mma.prnewswire.com/media/2343818/Johnson_and_Johnson_Logo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""At Johnson & Johnson, we are tackling the greatest unmet needs for patients living with depression, schizophrenia and bipolar disorder – with the ultimate goal of remission from disease," said Bill Martin, Ph.D., Global Therapeutic Area Head, Neuroscience, Johnson & Johnson Innovative Medicine. "Our data at ACNP this year showcases how we ar...